{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:12:00Z","timestamp":1792012320458,"version":"4.4.0"},"reference-count":18,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,24]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Venetoclax (Ven), when combined with intensive chemotherapy, shows promise for untreated acute myeloid leukemia (AML), but its integration with the 7+3 regimen remains underexplored. In a phase 1b study, we assessed the safety and efficacy of Ven with daunorubicin and cytarabine in patients with newly diagnosed AML. A total of 34 patients (median age, 59 years; 62% non-White) received Ven at escalating durations (8, 11, or 14 days). Adverse events included febrile neutropenia (100%), sepsis (29%), and enterocolitis (23.5%), but there were no induction deaths. The median recovery times for neutrophils (&amp;gt;1.0\u00a0\u00d7 103\/\u03bcL) and platelets (&amp;gt;100\u00a0\u00d7 103\/\u03bcL) were less than 30 days. Composite complete remission was achieved in 85.3% of patients, and 86.2% were negative for measurable residual disease (MRD). Responses spanned all European Leukemia Net 2022 risk categories. With a median follow-up of 9.6 (2-20) months, the median duration of response, event-free survival, and overall survival were not reached. Ven (400 mg), when combined with 7+3 chemotherapy, was safe and effective in achieving MRD-negative remissions across all durations. Ven dose optimization is being explored in the expansion phase of this trial. Future multicenter studies should confirm our findings. This trial was registered at clinicaltrials.gov as #NCT05342584.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024026700","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T21:13:51Z","timestamp":1738962831000},"page":"1870-1875","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8346-5767","authenticated-orcid":false,"given":"Ioannis","family":"Mantzaris","sequence":"first","affiliation":[{"name":"1Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mendel","family":"Goldfinger","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1640-3736","authenticated-orcid":false,"given":"Matan","family":"Uriel","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Shastri","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"},{"name":"2Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4723-6745","authenticated-orcid":false,"given":"Nishi","family":"Shah","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira","family":"Gritsman","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"},{"name":"3Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah S.","family":"Kornblum","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0138-8986","authenticated-orcid":false,"given":"Lauren","family":"Shapiro","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Alejandro","family":"Sica","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Munoz","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Chambers","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aradhika","family":"Dhawan","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhannine Alyssa","family":"Verceles","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Fehn","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balda","family":"Tirone","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2685-3856","authenticated-orcid":false,"given":"Lamisha","family":"Shah","sequence":"additional","affiliation":[{"name":"3Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaunmonique","family":"Clark","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxin","family":"Zhang","sequence":"additional","affiliation":[{"name":"4Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi","family":"Kim","sequence":"additional","affiliation":[{"name":"4Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis L.","family":"Cooper","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7592-7693","authenticated-orcid":false,"given":"Amit","family":"Verma","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"},{"name":"2Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"},{"name":"5Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Feldman","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"25","key":"2025042411215484600_bib1","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2025042411215484600_bib2","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematol"},{"issue":"6","key":"2025042411215484600_bib3","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3\u00a0+ 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2025042411215484600_bib4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-140646","article-title":"Maximal tolerated dose of the BCL-2 inhibitor venetoclax in combination with daunorubicin\/cytarabine induction in previously untreated adults with acute myeloid leukemia (AML) [abstract]","volume":"136","author":"Stone","year":"2020","journal-title":"Blood"},{"issue":"30","key":"2025042411215484600_bib5","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2025042411215484600_bib6","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2012-02-408336","article-title":"Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology\u00a0Group","volume":"120","author":"Loken","year":"2012","journal-title":"Blood"},{"key":"2025042411215484600_bib7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-1-4939-7142-8_10","article-title":"Detection and quantification of acute myeloid leukemia-associated fusion transcripts","volume":"1633","author":"Schumacher","year":"2017","journal-title":"Methods Mol Biol"},{"issue":"8","key":"2025042411215484600_bib8","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/bloodadvances.2018015925","article-title":"A\u00a0next-generation sequencing\u2013based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations","volume":"2","author":"Levis","year":"2018","journal-title":"Blood Adv"},{"issue":"12","key":"2025042411215484600_bib9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"25","key":"2025042411215484600_bib10","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","article-title":"A\u00a0randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206\u00a0patients","volume":"125","author":"Burnett","year":"2015","journal-title":"Blood"},{"issue":"13","key":"2025042411215484600_bib11","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"2025042411215484600_bib12","doi-asserted-by":"crossref","first-page":"1272072","DOI":"10.3389\/fonc.2023.1272072","article-title":"Impact of different chemotherapy regimens on intestinal mucosal injury assessed with bedside ultrasound: a study in 213 AML\u00a0patients","volume":"13","author":"Benedetti","year":"2023","journal-title":"Front Oncol"},{"issue":"7","key":"2025042411215484600_bib13","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase\u00a03\u00a0trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol"},{"issue":"1","key":"2025042411215484600_bib14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3748\/wjg.v23.i1.42","article-title":"Neutropenic enterocolitis","volume":"23","author":"Rodrigues","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"15","key":"2025042411215484600_bib15","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"10388","key":"2025042411215484600_bib16","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly\u00a0diagnosed patients with FLT3-internal-tandem-duplication-positive acute\u00a0myeloid\u00a0leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"15","key":"2025042411215484600_bib17","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","article-title":"Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations","volume":"36","author":"Freeman","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"2025042411215484600_bib18","doi-asserted-by":"crossref","first-page":"106971","DOI":"10.1016\/j.leukres.2022.106971","article-title":"Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling","volume":"123","author":"Ganzel","year":"2022","journal-title":"Leuk Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/17\/1870\/2370323\/blood_bld-2024-026700-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/17\/1870\/2370323\/blood_bld-2024-026700-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T15:22:01Z","timestamp":1745508121000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/17\/1870\/535523\/Venetoclax-plus-daunorubicin-and-cytarabine-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":18,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025,4,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024026700","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]}}}